Extracellular Vesicle STAT6 ASO Delivery for Stable Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for delivering antisense oligonucleotides (ASOs) to target STAT6 transcripts face challenges in stability and targeting, limiting their therapeutic effectiveness in treating diseases and enhancing immune responses.

Innovation Solution

Administering ASOs targeting STAT6 transcripts, linked to the surface of extracellular vesicles (EVs) such as exosomes, in doses ranging from 0.01 mg to 240 mg, to enhance delivery and targeting, with up to 90% of ASOs associated with EVs, and optionally using scaffold proteins and exogenous targeting moieties to specific tissues or cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If ASOs are administered to target STAT6 transcripts, then therapeutic effectiveness is improved, but stability and targeting are insufficient

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidASO stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent uses extracellular vesicles (EVs) as intermediary carriers to deliver ASOs to target cells. The EVs protect ASOs from degradation in the bloodstream and facilitate their entry into target cells, thereby improving both stability and therapeutic effectiveness. This is achieved by loading ASOs into EVs or conjugating them to EV surfaces, allowing the ASOs to reach their STAT6 transcript targets without being degraded by nucleases in the circulation.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If ASOs are administered to target STAT6 transcripts, then therapeutic effectiveness is improved, but targeting precision is insufficient

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidtargeting precision

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent employs surface engineering of EVs with specific ligands, antibodies, or peptides that recognize and bind to receptors on target cells. This local modification of EV surfaces enables precise targeting to specific cell types (such as cancer cells) while leaving other cells unaffected. The ASOs are delivered specifically to the intended target cells through this targeted approach, improving both targeting precision and therapeutic effectiveness.

Inventive Principle:

Principle #3Local quality

3Productivity

If ASOs are linked to EV surfaces, then delivery efficiency is improved, but device complexity increases

Engineering Contradiction:

Improvedelivery efficiencyVSAvoiddelivery system complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent utilizes the natural biological properties of EVs to achieve ASO delivery. EVs are naturally produced by cells and have inherent capabilities for stable circulation, cell uptake, and tissue penetration. By leveraging these self-service properties of EVs rather than requiring complex artificial delivery systems, the patent achieves high delivery efficiency while keeping the overall system relatively simple. The EVs themselves provide the necessary functions for protected ASO delivery without requiring additional complex engineering components.

Inventive Principle:

Principle #25Self-service

Data Source

PatentUS20250382613A1Methods of using extracellular vesicle-ASO targeting STAT6

Publication Date: 2025.12.18 LONZA SALES AG

AI summary

The present disclosure relates to methods of administering an antisense oligonucleotide (ASO) comprising a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within a STAT6 transcript. In some aspects, the ASO is associated with an extracellular vesicle, e.g., exosome.